Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
Sonia Jaramillo(Heidelberg University), Richard F. Schlenk(German Cancer Research Center), Markus Schaich(Rems-Murr-Klinikum), Sabine Käyser(German Cancer Research Center), Lukas Baumann(Statistics Austria), Carsten Müller‐Tidow(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Lucian Le Cornet(German Cancer Research Center), Markus Kratzmann(German Cancer Research Center), Meinhard Kieser(Heidelberg University), Christoph Schliemann(University Hospital Münster), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Martina Crysandt(RWTH Aachen University), Olga Eissymont(Heidelberg University), Martin Görner(Klinikum Bielefeld), Tobias Gaska(Brüderkrankenhaus St. Josef Paderborn), Jens Chemnitz(Gemeinschaftsklinikum Mittelrhein), Alexander Hoellein(Red Cross Hospital), Johannes Krisam(University Hospital Heidelberg)
Cited by 1
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k